Catherine Matthews, MD
Urogynecology and Reconstructive Pelvic Surgery · Winston Salem, NCNPI 1467563593
Payments from drug & device makers
Across 181 payments — averaging $5268.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$663K
- Coloplast$265K
- Urovant Sciences Inc$13K
- Sumitomo Pharma America, Inc.$7K
- Intuitive Surgical$3K
- Medtronic$1K
- plus $1K from 4 others
Across 22 payments — averaging $14,792 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Coloplast$325K
What the payments were for
- Consulting fees$44,39563%
- Speaking & faculty fees$9,44513%
- Travel & lodging$12,24517%
- Food & beverage$4,2626%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 42 | $662,780 |
| Coloplast | 88 | $265,371 |
| Urovant Sciences Inc | 5 | $12,782 |
| Sumitomo Pharma America, Inc. | 7 | $6,555 |
| Intuitive Surgical | 14 | $3,239 |
| Medtronic | 13 | $1,402 |
| Axonics, Inc. | 8 | $1,263 |
| Renovia Inc | 2 | $104 |
| Palette Life Sciences, Inc. | 1 | $26 |
| AbbVie | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ALTIS$19,403
- GENERAL PELVIC ORGAN PROLAPSE$8,129
- Solyx SIS System$4,000
- GENERAL FEMALE SUI$3,150
- Da Vinci Surgical System$2,979
- UPSYLON$2,800
- SOLYX$2,000
- OBTRYX$800
- Axonics$773
- Advantage System$750
- TITAN$215
- ADVANTAGE FIT$200
- Bulkamid$117
- Signia$105
- Leva Pelvic Floor Trainer$104
- Axonics r-SNM System$101
- GENERAL - THERAPIES$100
How this compares
$953,538 in reported general payments places this provider in the 95th percentile of 35 urogynecology and reconstructive pelvic surgery providers in North Carolina.
See all urogynecology and reconstructive pelvic surgery providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 241 | $145,289 |
| GemtesaVibegron | 170 | $116,269 |
| Estradiol | 231 | $15,536 |
| Methenamine Hippurate | 61 | $3,021 |
| Desmopressin Acetate | 40 | $2,269 |
| Clobetasol Propionate | 19 | $1,110 |
| Trimethoprim | 19 | $1,094 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 77 | $952 |
| NitrofurantoinNitrofurantoin Macrocrystal | 19 | $555 |
| Oxybutynin Chloride ErOxybutynin Chloride | 24 | $487 |
| Solifenacin Succinate | 23 | $381 |
| Cephalexin | 58 | $380 |
| Imipramine Hcl | 11 | $224 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 44 | $187 |
| Amitriptyline Hcl | 14 | $135 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $6,555 | $116,269170 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 35 urogynecology and reconstructive pelvic surgery providers in North Carolina.
Other urogynecology and reconstructive pelvic surgery in Winston Salem
- Rahul DuttaWinston Salem$13K
- Candace Parker-AutryWinston Salem$2K
- Nazema SiddiquiDurham$1.1M
- Cindy AmundsenDurham$323K
- Cary FishburneCharlotte$231K
- William PorterCharlotte$177K
- Erinn MyersCharlotte$30K
- Amie KawasakiDurham$27K
- Jennifer WuChapel Hill$14K
- Sarah BradleyCary$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.